Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 849 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Prospective Blood Draw Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effects of Increased, Egg-Based Protein Intake on Muscle Composition,

NCT01396915
View directory record Official record
Conditions
Muscle Composition, Sarcopenia, Hypertrophy, Inflammation
Interventions
Dietary Protein Intake
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
55 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Nov 7, 2026, 5:01 AM EST
Completed Not applicable Interventional

COOL-BP Study: Continuous Versus Occasional Blood Pressure Study

NCT05211648
View directory record Official record
Conditions
Hypertension
Interventions
Aktiia Bracelet
Device
Lead sponsor
Aktiia SA
Industry
Eligibility
26 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Nov 7, 2026, 5:01 AM EST
Terminated No phase listed Observational

ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing

NCT05380557
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Cancer
Interventions
Germline genetic testing
Diagnostic Test
Lead sponsor
Invitae Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Nov 7, 2026, 5:01 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Wearable Technology in Endoscopy

NCT05044104
View directory record Official record
Conditions
Healthy
Interventions
Consumer-facing wearable smart watch
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Nov 7, 2026, 5:01 AM EST
Terminated Not applicable Interventional

Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients

NCT03566407
View directory record Official record
Conditions
Crohn's Disease
Interventions
Colonoscopy
Procedure
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Ventura, California • Hamden, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Nov 7, 2026, 5:01 AM EST
Completed Phase 3 Interventional Results available

IGIV Study for Chronic ITP Patients Ages 3-70

NCT00511147
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
IGIV3I Grifols 10%
Biological
Lead sponsor
Grifols Biologicals, LLC
Industry
Eligibility
3 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Nov 7, 2026, 5:01 AM EST
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Nov 7, 2026, 5:01 AM EST
Completed Phase 4 Interventional Results available

Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis

NCT00589628
View directory record Official record
Conditions
Chronic Uveitis
Interventions
infliximab
Drug
Lead sponsor
Egla C. Rabinovich
Other
Eligibility
4 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Nov 7, 2026, 5:01 AM EST
Completed Phase 2 Interventional

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

NCT05709444
View directory record Official record
Conditions
Kidney Disease
Interventions
Bremelanotide, RAAS inhibition therapy
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Chula Vista, California • La Mesa, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Nov 7, 2026, 5:01 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

NCT05171972
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Ofatumumab
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 7, 2026, 5:01 AM EST
Completed Phase 4 Interventional Results available

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

NCT00357656
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant Protein-Free Factor VIII (rAHF-PFM)
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Nov 7, 2026, 5:01 AM EST
Completed Not applicable Interventional Results available

Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients

NCT03257410
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Theranova 400 dialyzer, Elisio-17H dialyzer
Device
Lead sponsor
Vantive Health LLC
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Corona, California • Riverside, California • Bloomfield, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Nov 7, 2026, 5:01 AM EST
Completed Phase 3 Interventional Results available

A Study in Adults With Type 2 Diabetes

NCT01421459
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, Lantus, OAMs
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Nov 7, 2026, 5:01 AM EST
Completed Phase 3 Interventional Results available

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

NCT02783482
View directory record Official record
Conditions
Immunologic Deficiency Syndromes
Interventions
GC5107
Biological
Lead sponsor
Green Cross Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
10
States / cities
Centennial, Colorado • North Palm Beach, Florida • Plymouth, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Nov 7, 2026, 5:01 AM EST
Recruiting No phase listed Observational

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

NCT06635954
View directory record Official record
Conditions
Cancer, Immunotherapy, PD-1, PD-L1, Immune Checkpoint Therapy
Interventions
Not listed
Lead sponsor
Oxford Biodynamics Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Norwich, Connecticut • Dublin, Georgia • Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Nov 7, 2026, 5:01 AM EST
Completed Not applicable Interventional

The Acute Burn ResUscitation Multicenter Prospective Trial

NCT04356859
View directory record Official record
Conditions
Burn Injury
Interventions
Albumin Human
Drug
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
24
States / cities
Phoenix, Arizona • Sacramento, California • Torrance, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 7, 2026, 5:01 AM EST
Completed Phase 4 Interventional Results available

Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration

NCT00473642
View directory record Official record
Conditions
Age-Related Maculopathy, Choroidal Neovascularization
Interventions
Ranibizumab, Verteporfin
Drug
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Nov 7, 2026, 5:01 AM EST
Active, not recruiting No phase listed Observational

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

NCT05112237
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Not listed
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
0 Years to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 7, 2026, 5:01 AM EST
Completed Phase 4 Interventional Results available

Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery

NCT00958581
View directory record Official record
Conditions
Scoliosis
Interventions
Tranexamic Acid, Normal Saline, Epsilon aminocaproic acid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
10 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Nov 7, 2026, 5:01 AM EST
Terminated Phase 4 Interventional Results available

Ketamine for Pain in the Emergency Department

NCT03896230
View directory record Official record
Conditions
Acute Pain
Interventions
Ketamine Injectable Product
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Nov 7, 2026, 5:01 AM EST
Recruiting No phase listed Observational

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

NCT03680677
View directory record Official record
Conditions
Leukemia, Acute, MDS
Interventions
Bone Marrow or Peripheral Blood Graft (BMT), Cancer-directed Therapy or Best Supportive Care, Frailty Assessment
Procedure · Other · Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 7, 2026, 5:01 AM EST
Terminated No phase listed Observational

Immune Modulators and IVF

NCT02626702
View directory record Official record
Conditions
In Vitro Fertilization
Interventions
Observational
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Nov 7, 2026, 5:01 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

NCT06151223
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
Bio-specimen Collection: Blood, Bio-specimen Collection: Pancreatic Juice, MRI
Other · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 7, 2026, 5:01 AM EST